| アブストラクト | The use of antipsychotic medications (APMs) could be different among countries due to availability, approved indications, characteristics and clinical practice. However, there is limited literature providing comparisons of APMs use among countries. To examine trends in antipsychotic prescribing in Taiwan, Hong Kong, Japan, and the United States, we conducted a cross-national study from 2002 to 2014 b y using the distributed network approach with common data model. We included all patients who had at least a record of antipsychotic prescription in this study, and defined patients without previous exposure of antipsychotics for 6 months before the index date as new users for incidence estimation. We calculated the incidence, prevalence, and prescription rate of each medication by calendar year. Among older patients, sulpiride was the most incident [incidence rate (IR) 11.0-23.3) and prevalent [prevalence rate (PR) 11.9-14.3) APM in Taiwan, and most prevalent (PR 2.5-3.9) in Japan. Quetiapine and haloperidol were most common in the United States (IR 8.1-9.5; PR 18.0-18.4) and Hong Kong (PR 8.8-13.7; PR 10.6-12.7), respectively. The trend of quetiapine use was increasing in Taiwan, Hong Kong and the United States. As compared to older patients, the younger patients had more propensity to be prescribed second-generation APM for treatment in four countries. Trends in antipsychotic prescribing varied among countries. Quetiapine use was most prevalent in the United States and increasing in Taiwan and Hong Kong. The increasing use of quetiapine in the elderly patients might be due to its safety profile compared to other APMs. |
|---|
| 投稿者 | Su, Chien-Chou; Chia-Cheng Lai, Edward; Kao Yang, Yea-Huei; Man, Kenneth K C; Kubota, Kiyoshi; Stang, Paul; Schuemie, Martijn; Ryan, Patrick; Hardy, Chantelle; Zhang, Yinghong; Kimura, Shinya; Kamijima, Yukari; Wong, Ian C K; Setoguchi, Soko |
|---|
| 組織名 | Department of Pharmacy, National Cheng Kung University Hospital, College of;Medicine, National Cheng Kung University, Tainan, Taiwan; Institute of Clinical;Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung;University, Tainan, Taiwan; School of Pharmacy And, College of Medicine National;Cheng Kung University, Tainan, Taiwan; Health Outcome Research Center, National;Cheng Kung University, Tainan, Taiwan.;Cheng Kung University, Tainan, Taiwan. Electronic address:;yhkao@mail.ncku.edu.tw.;Centre for Safe Medication Practice and Research, Department of Pharmacology and;Pharmacy, University of Hong Kong, Hong Kong; Research Department of Practice and;Policy, UCL School of Pharmacy, London, United Kingdom.;NPO Drug Safety Research Unit Japan, Tokyo, Japan.;Janssen Research & Development, LLC, Titusville, United States.;Duke Clinical Research Institute, Durham, United States.;Japan Medical Data Center, Tokyo, Japan.;Department of Medicine, Rutgers Robertood Johnson Medical School and Institute;for Health, Health Care Policy and Aging Research, Rutgers Biomedical and Health;Sciences, New Jersey, United States. |
|---|
